MRT-2359 + Apalutamide for Prostate Cancer

(MODeFIRe-1 Trial)

This trial tests a new treatment for prostate cancer that resists traditional hormone therapy. Participants will receive a combination of MRT-2359, an experimental drug, and apalutamide, a current prostate cancer medication, to determine if it can lower prostate-specific antigen (PSA) levels, which indicate cancer activity. The trial also examines the safety, tolerability, and effectiveness of this treatment against tumors. It suits those with prostate cancer that has resisted treatment, particularly if they have undergone ongoing hormone therapy but limited chemotherapy. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to significant advancements in prostate cancer therapy.

Research has shown that MRT-2359, when combined with apalutamide, is generally well-tolerated. Studies indicate that side effects are usually mild and not serious, often involving minor stomach issues. Other research suggests that MRT-2359 is generally safe for use. Apalutamide, already used to treat prostate cancer, has a well-established safety profile. Overall, current evidence suggests that the combination of these two treatments appears safe.¹²³⁴⁵

Researchers are excited about the combination of MRT-2359 and apalutamide for prostate cancer because it introduces a novel approach to treating castration-resistant prostate cancer. Unlike traditional treatments that primarily focus on hormone therapy to control cancer growth, MRT-2359 works by potentially targeting a different aspect of cancer cell survival, offering a fresh mechanism of action. By combining it with apalutamide, which already blocks androgen receptors, this combo could enhance treatment effectiveness and overcome resistance seen with current therapies. This innovative approach might offer renewed hope for patients who have limited options.

Research has shown that MRT-2359, when combined with apalutamide, may help treat prostate cancer. In earlier studies, MRT-2359 reduced proteins linked to prostate cancer growth and controlled the disease in 67% of patients, with many experiencing tumor shrinkage. Another study found that MRT-2359, when paired with a similar drug called enzalutamide, lowered PSA levels in all patients. Apalutamide alone is already known for its effectiveness, with high survival rates and ongoing treatment among patients. This trial will evaluate the combination of MRT-2359 with apalutamide, suggesting that this approach could be effective for prostate cancer resistant to standard hormone therapy.¹³⁵⁶⁷